Piper Sandler Maintains Overweight on AnaptysBio, Raises Price Target to $95

Piper Sandler analyst Yasmeen Rahimi has maintained an Overweight rating on AnaptysBio (NASDAQ: ANAB) and increased the price target from $67 to $95. This adjustment reflects a positive outlook on the company's performance.